621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
If the results demonstrate a positive safety and efficacy profile, this study could pave the way for a novel adjunctive treatment strategy for a particularly challenging patient population. Adults with Type 1 Diabetes…
Establishing bioequivalence is crucial for pharmaceutical products, especially when manufacturing processes are altered, as it confirms that the drug's performance remains consistent. This finding means that patients …
This study provides crucial insights for plastic surgeons and patients, indicating that GLP-1 RA-induced weight loss may be associated with a slightly lower incidence of minor complications following body contouring s…
This comprehensive analysis provides crucial evidence for clinicians and patients in selecting the most effective GLP-1 receptor mono-agonist formulation for cardiometabolic improvement. The findings highlight the sup…
This study provides strong evidence that GLP-1 Receptor Agonists, exemplified by semaglutide, can directly improve cardiac function and clinical outcomes in patients with HFrEF, beyond their established metabolic bene…
This systematic review underscores the transformative potential of GLP-1 receptor agonists in the management of obesity and its associated health complications. The consistent and significant weight loss observed, cou…
This research highlights a potentially significant benefit of GLP-1 receptor agonists in a high-risk population with advanced heart failure. While primarily known for managing diabetes and obesity, these findings sugg…
This "complex clinical encounter series" brings to the forefront a crucial, yet often underappreciated, aspect of GLP-1 RA therapy: its potential long-term impact on bone health. The key implication is that current cl…
This study holds significant promise for improving the lives of individuals with Type 1 Diabetes. If successful, the combination of a GLP-1 receptor agonist and an SGLT2 inhibitor with AID could offer a novel and high…
The identification of genetic predictors for GLP-1 response holds significant implications for personalized medicine in managing prediabetes, type 2 diabetes, and obesity. This research could lead to tailored therapeu…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This real-world evidence confirms the effectiveness and safety of oral semaglutide in a diverse Mexican adult population, closely mirroring the positive outcomes observed in more controlled clinical trials. The signif…
This review underscores the increasing importance of real-world evidence (RWE) in shaping healthcare decisions, from reimbursement to regulatory approval. By demonstrating how RWE is being effectively utilized and ide…
This comprehensive network meta-analysis provides crucial evidence for guiding treatment decisions in a high-risk patient population. The findings strongly support the preferential use of SGLT2 inhibitors and GLP-1 re…
This study provides crucial mechanistic insights, demonstrating that semaglutide exerts direct hepatoprotective actions via GLP-1 receptors on intrahepatic sinusoidal endothelial cells, independent of its weight-reduc…
This research is highly significant as it identifies semaglutide as a promising novel candidate for treating cocaine use disorder. Given the severe lack of effective pharmacological interventions for addiction, these …
This commentary underscores the urgent need for a proactive public health strategy to manage the societal implications of GLP-1RA proliferation. The authors argue that without clear guidelines and public education, th…
This comprehensive real-world analysis provides crucial insights into the differential cardiovascular benefits of two cornerstone drug classes for Type 2 Diabetes. The findings highlight that GLP-1 RAs may be more eff…
The widespread use of GLP-1 RAs for managing diabetes and obesity makes understanding their perioperative implications critically important for patient safety. This study directly addresses the potential for increased…
This research is crucial because it addresses a significant unmet need for effective and safe treatments for obesity and cardiovascular risk in individuals with Type 1 Diabetes. If Semaglutide proves effective in impr…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
This Phase 1 study is a critical foundational step for advancing NNC0480-0389 as a potential combination therapy. If the drugs can be safely co-administered without adverse pharmacokinetic interactions, it significant…
This study is crucial because it seeks to uncover a novel mechanism by which semaglutide promotes weight loss, specifically through its impact on brown adipose tissue (BAT). Understanding this pathway could lead to mo…
This study holds significant promise for overweight and obese women struggling with infertility, potentially offering a novel therapeutic strategy to improve IVF success rates. If Semaglutide pre-treatment proves effe…
This diagnostic study, while listed as completed, has not yet published its specific findings regarding gastric contents in patients on semaglutide, with the official completion date set for 2025-05-31. However, the f…
Optimizing early T2DM management is crucial for preventing long-term complications and improving patient quality of life. This trial could provide critical evidence for the benefits of aggressive, early combination th…
This study is significant because it provides valuable real-world evidence on Semaglutide's effectiveness, complementing the data from highly controlled clinical trials. Understanding how a drug performs in diverse pa…
The MAINTAIN study addresses a critical unmet need in obesity management, offering a potential solution to the widespread problem of weight regain after discontinuing GLP-1 RAs. GFMA could provide a durable, non-pharm…
This real-world data provides crucial insights into the comparative effectiveness of two powerful drug classes for diabetic patients post-ACS. The findings suggest that while both Semaglutide and SGLT2 inhibitors offe…
This study provides compelling evidence that revisional bariatric surgery offers superior long-term weight loss and metabolic comorbidity resolution compared to semaglutide for patients experiencing recurrent weight g…
The study demonstrated significant improvements across multiple endpoints for the semaglutide group. Semaglutide treatment led to a substantial improvement in heart failure symptoms and physical limitations, with the …
Semaglutide is currently not FDA-approved for Type 1 Diabetes, making this research critical for exploring new therapeutic avenues in a population with significant unmet medical needs. If the trial demonstrates positi…
The potential success of oral semaglutide in effectively managing overweight and obesity would represent a monumental advancement in metabolic medicine, offering a highly convenient, non-injectable treatment option. A…
The widespread adoption of GLP-1 receptor agonists means plastic surgeons are increasingly encountering patients with significant, rapid weight loss, necessitating a paradigm shift in surgical planning. This review pr…
This study provides valuable real-world evidence, reinforcing Semaglutide's efficacy not only in achieving substantial weight loss but also in improving critical metabolic parameters and, importantly, the overall heal…
The findings from this study are incredibly significant as they underscore the potential of Semaglutide as a highly effective treatment option for adolescent obesity, a condition with limited pharmacological solutions…
This study provides valuable real-world insights into the comparative safety profiles of tirzepatide, semaglutide, and liraglutide, which can complement findings from controlled clinical trials. The observed differenc…
This review provides crucial, evidence-based practical guidance for clinicians navigating the complex, often challenging, management of patients with concurrent CKD and T2D. By synthesizing the latest research and off…
This study provides compelling evidence that semaglutide is highly effective in reversing advanced MASH pathology, including significant liver fibrosis, in a robust and clinically relevant animal model. The observed i…
The successful demonstration of semaglutide's safety and tolerability in CFRD patients would be a significant step forward, potentially offering a novel therapeutic avenue beyond insulin. If proven safe and effective …